SecBot SecBot
PRESS-RELEASE ·Filed Apr 14, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The CAR-MSC platform significantly strengthens Mesoblast’s R&D pipeline and technological moat in allogeneic cell therapy. While share issuance introduces dilution, the absence of cash cost and addition of high-potential IP makes this a strategically positive move. Monitor upcoming preclinical data and potential clinical milestones as key catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.75
T+0 close · Apr 14, 2026 · via day close
Latest settled
−1.97%
T+60 · $15.44
Vs SPY
−10.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $15.75entry
  2. T+1 · 7mo ago +2.16%α +1.91% · $16.09
  3. T+5 · 7mo ago −0.06%α −1.70% · $15.74
  4. T+20 · 6mo ago −8.32%α −14.36% · $14.44
  5. T+60 · 4mo ago −1.97%α −10.11% · $15.44
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast announced an exclusive worldwide license to a patented CAR-MSC technology platform from Mayo Clinic, acquired via issuance of ASX ordinary shares. The deal enhances Mesoblast's cell therapy pipeline with potential for improved targeting in inflammatory diseases like ulcerative colitis, Crohn’s, and lupus nephritis.

Key Facts

  • Mesoblast acquired exclusive worldwide rights to a CAR-MSC technology platform developed at Mayo Clinic.
  • The acquisition was made through issuance of ASX ordinary shares (no cash outlay disclosed).
  • Technology aims to enhance MSC homing and potency in inflammatory and autoimmune diseases, including bowel diseases and lupus nephritis.
  • Mayo Clinic will provide in-kind support, including GMP manufacturing assistance.
  • Mayo Clinic holds financial interest in the technology via licensing agreement.

Financial Impact

Undisclosed dilution from share issuance; no cash outflow reported.

dilutionintellectual_propertyR&D_pipeline

Risk Factors

  • Dilution risk from share-based acquisition, magnitude unknown.
  • Early-stage technology: CAR-MSC is preclinical, with no guarantee of clinical success.
  • Forward-looking statements dominate; near-term financial impact is minimal.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274064

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026